Doxofylline 400 mg
| Composition | Doxofylline 400 mg |
|---|---|
| Packing | 10x10 Blister |
| MRP | ₹ 800 |
| Dosage Form | Tablets |
Ziafyl-400 Tablet contains Doxofylline 400 mg, a next-generation xanthine bronchodilator used to manage asthma and chronic obstructive pulmonary disease (COPD). Doxofylline is a newer and better-tolerated derivative of theophylline that relaxes the airways and makes breathing easier, with a significantly improved cardiovascular and gastrointestinal side effect profile.
Ziafyl-400 is prescribed for patients with obstructive airway diseases who need sustained bronchodilation to maintain open airways and reduce the frequency of breathing difficulties. Its once-daily or twice-daily dosing and improved tolerability over traditional xanthines make it a preferred oral bronchodilator in clinical practice.
This medicine is commonly used for:
Doxofylline 400 mg is indicated for the treatment of bronchial asthma, COPD, chronic bronchitis, and other obstructive pulmonary conditions associated with reversible bronchoconstriction. It is used as a bronchodilator to reduce airway resistance, improve forced expiratory volume, and relieve symptoms of dyspnoea and wheezing in adults.
Doxofylline relaxes the muscles surrounding the airways in the lungs, allowing them to open up and making it easier to breathe. It also reduces the body's tendency to overproduce chemicals that tighten the airways. Unlike older xanthine medicines, Doxofylline in Ziafyl-400 is designed to be gentler on the heart and stomach.
Doxofylline is a xanthine derivative that inhibits phosphodiesterase (PDE) enzymes — primarily PDE3 and PDE4 — in bronchial smooth muscle cells, leading to elevated cyclic AMP and cyclic GMP levels. This activates protein kinase A, phosphorylates myosin light chain kinase (MLCK), and inhibits myosin-actin cross-bridge formation, causing airway smooth muscle relaxation. Unlike theophylline, Doxofylline has minimal affinity for adenosine A1 and A2 receptors, which explains its markedly lower incidence of cardiac arrhythmias, tachycardia, and CNS stimulation. It may also have mild anti-inflammatory properties via inhibition of TNF-alpha and IL-5 in airway tissues.
Doxofylline was developed to overcome the well-known limitations of theophylline — its narrow therapeutic window and frequent side effects on the heart and nervous system. By avoiding adenosine receptor binding (the main culprit behind theophylline's cardiac and CNS effects), Doxofylline in Ziafyl-400 offers comparable bronchodilation with a much cleaner safety profile.
Ziafyl-400 is typically taken once or twice daily as directed by your doctor, with or after food to reduce the risk of stomach upset. Take it at regular intervals and at the same time each day. Do not stop or adjust the dose without consulting your doctor.
Always follow the dosage and schedule advised by your doctor — this is general guidance only.
Doxofylline is generally well tolerated. Occasional side effects may include nausea, stomach discomfort, headache, dizziness, or palpitations. These are less frequent and less severe than with older xanthines like theophylline. Tell your doctor if any side effect is severe or persistent.
All xanthine bronchodilators cause dangerous heart palpitations.
Older xanthines like theophylline are known for cardiac effects because they block adenosine receptors. Doxofylline in Ziafyl-400 has minimal adenosine receptor affinity, making it significantly safer for the heart at therapeutic doses.
Bronchodilators treat and cure the underlying lung disease.
Bronchodilators like Doxofylline relax the airways and relieve breathing symptoms — they do not cure asthma or COPD. Managing these conditions requires a comprehensive plan including bronchodilators, anti-inflammatory medicines, and lifestyle adjustments guided by your doctor.